For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Dong-A St Co., Ltd.

Calculating rank

USPTO Granted Patents = 24

% Expired Patents = 16.7

CIPO Patents = 3

EPO Patents = 18

Trademarks = 1

Forward Citations = 26

Loading Chart...

Loading Chart...

152 inventors (with patents filed for the assignee):

Soon-Hoe Kim (8 out of 10 patents)

Weon-Bin Im (5 out of 6 patents)

Mi-Won Son (4 out of 4 patents)

4. Sun-Ho Choi (3 out of 5 patents)

5. Min-Jung Lee (3 out of 14 patents)

6. Sang-Zin Choi (3 out of 3 patents)

7. Hye-Ju Kim (3 out of 4 patents)

8. Ja-Young Ryu (3 out of 3 patents)

9. Sun-Yeou Kim (3 out of 5 patents)

10. Sung-Hak Choi (3 out of 5 patents)

11. Jung-Sang Park (3 out of 3 patents)

12. Sun-Woo Jang (3 out of 5 patents)

13. Hae-Sun Kim (3 out of 4 patents)

14. Ji Hye Lee (2 out of 99 patents)

15. Tae-hyoung Kim (2 out of 16 patents)

24 patents: Sort by Forward Citations

1. 12240836 - Compounds as GCNinhibitors, pharmaceutical compositions and uses thereof (2025-03-04),

2. 12168073 - Percutaneous absorption preparation comprising stabilized donepezil (2024-12-17),

3. 12115159 - Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing GPR119 ligand as active ingredient (2024-10-15),

4. 11992562 - Percutaneous absorption preparation for treating dementia comprising donepezil (2024-05-28),

5. 11840574 - Anti-DR5 antibody and use thereof (2023-12-12),

6. 11713344 - Acylated oxyntomodulin peptide analog (2023-08-01),

7. 11236142 - Acylated oxyntomodulin peptide analog (2022-02-01),

8. 10894768 - Salt of (R)-(-methylpyrrolidine--yl)methyl(-chloro--fluoro-[-biphenyl]--yl)carbamate and crystal form thereof (2021-01-19),

9. 10813973 - Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy (2020-10-27),

10. 10709752 - Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders (2020-07-14),

11. 10660928 - Pharmaceutical composition containing combination extracts of Moutan Root Bark, Angelica Dahurica Root, bupleurum root or fractions thereof for prevention and treatment of neurodegenerative disorder (2020-05-26),

12. 10428055 - Substituted piperidines having GPR119 agonistic activity (2019-10-01),

13. 10398747 - Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy (2019-09-03),

14. 10160724 - Tetrahydropyridine derivatives and their use as antibacterial agents (2018-12-25),

15. 10159667 - Composition containing a DPP-IV inhibitor for preventing or treating renal diseases (2018-12-25),

Company Overview

Dong-A St Co., Ltd. is a prominent South Korean company specializing in the development and manufacturing of pharmaceuticals and healthcare products. With a focus on innovative drug formulations and therapeutic solutions, the company is dedicated to enhancing health outcomes through research-driven initiatives. Dong-A St operates primarily in the pharmaceutical sector, contributing to various therapeutic areas and striving to meet the evolving needs of patients and healthcare providers in both domestic and international markets.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

24 Patents

#201 in Seoul

#548 in South Korea

#26,701 in the World

Seoul, South Korea

Dong-A St Co., Ltd.

Forward Citations = 26

152 inventors:

Soon-Hoe Kim (8 out of 10 patents)

Weon-Bin Im (5 out of 6 patents)

Mi-Won Son (4 out of 4 patents)

4. Sun-Ho Choi (3 out of 5 patents)

5. Min-Jung Lee (3 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dong-A St Co., Ltd.. Retrieved from https://idiyas.com/company/dong-a-st-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…